Developer docs
API playgroundTry for free, no card

Search company profiles

Renew Biotechnologies

Full company profile

uuid000h112

Namestring
Renew Biotechnologies
Legal namestring
Renew Biotechnologies
Websiteurl
renewbt.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Renew Biotechnologies, founded in 2022 and headquartered in Provo, Utah, develops diagnostic and translational research solutions built on its proprietary NESSI-Seq native-read sequencing platform, which leverages Oxford Nanopore long-read technology to simultaneously detect DNA sequence, methylation, and hydroxymethylation patterns without bisulfite conversion or PCR amplification biases. The portfolio includes three commercial products — NeuroLens (a blood-based liquid biopsy for detecting neuron- and glia-derived cfDNA signals linked to active neurodegeneration in Alzheimer's, Parkinson's, and ALS), RNA Clarity (a native RNA sequencing workflow for RNA therapeutic characterization, QC, and lot release), and MethylMap (native-read methylation sequencing for translational methylation programs) — alongside a service catalogue spanning whole-genome, whole methylome, cfDNA methylation, targeted methylation, direct RNA, cDNA, and telomere sequencing, delivered through a 20,000-square-foot CAP/CLIA-certified Renew Labs facility with a custom in-house LIMS. The company also operates a wholly-owned subsidiary, Resonant, focused on neurodegenerative disease blood testing, and serves as the clinical testing provider for Path Fertility's NOA Guide epigenetic diagnostic for non-obstructive azoospermia.

The business operates a hybrid revenue model: professional-services revenue from CAP/CLIA clinical testing and end-to-end sequencing projects, supplemented by product/kits and reagents sales (NeuroLens, RNA Clarity, MethylMap). Pricing is fully quote-based and project-specific with no published tiers, and the company sells through a hybrid direct enterprise sales motion and channel partners, most notably Boston Heart Diagnostics for NeuroLens distribution and Valinor Discovery as an exclusive AI co-development partner authorized to train predictive models on jointly-owned neurological multi-omics datasets. Customers are segmented horizontally across biopharma and drug development companies, academic and clinical research institutions, healthcare providers and clinical laboratories, and fertility clinics, with sales cycles supported by content marketing, scientific publications, conference presentations, and website-driven partnership inquiries.

Strategically, the company is executing an offensive expansion rather than a defensive pivot: it has added new product lines (proteomics "available soon"), a new clinical vertical (reproductive health via Path Fertility), a new brand (Resonant) targeting neurodegeneration, a core technology partnership with Oxford Nanopore, supporting technology integrations with Agilent and Twist Bioscience, academic validation collaborations with BYU and the University of Kansas Alzheimer's Disease Research Center, and an exclusive data/AI partnership with Valinor Discovery — collectively pointing to a coordinated push to translate proprietary native-read sequencing into both clinical diagnostics and data-anchored biopharma services.

Short descriptiontext

Renew Biotechnologies develops native-read and long-read sequencing-based diagnostic products and services, including NeuroLens (neurodegeneration liquid biopsy), RNA Clarity, and MethylMap, serving biopharma, academic researchers, and clinical laboratories through a CAP/CLIA-certified lab.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersProvo, United States
HQ citystring
Provo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
genomic sequencing services, epigenetic diagnostics, liquid biopsy testing, native-read methylation, clinical laboratory services
Industry3 codes
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Genomic Sequencing & Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Testing Services
TypeProfessional Services
Description

CAP/CLIA certified laboratory services providing clinical-grade genomic and epigenetic analysis for diagnostic and monitoring applications, including NeuroLens neuron cell-death testing and Path Fertility NOA Guide diagnostic services.

renewbt.com
2Sequencing Services
TypeProfessional Services
Description

End-to-end sequencing services supporting genomic, epigenomic, and transcriptomic analysis from experimental design through bioinformatics and data delivery. Includes direct whole methylome sequencing, whole genome sequencing, direct RNA sequencing, and cDNA sequencing.

renewbt.com
3Products
TypeOne Time License
Description

Sale of proprietary kits and reagents including NeuroLens (neuron cell-death test), RNA Clarity (RNA vaccine QC), and MethylMap (methylation sequencing) products for customer use in their own laboratories.

renewbt.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1NeuroLens®
Description

Blood-based liquid biopsy test for detecting neuron- and glia-associated cfDNA signals linked to active neurodegeneration

renewbt.com
+4 more records
Core offering1 text field

Renew Biotechnologies develops and delivers clinical diagnostic products and sequencing services built on its proprietary native-read and long-read sequencing platform (NESSI-Seq / Direct Whole Methylome Sequencing). The company sells diagnostic products such as NeuroLens (blood-based liquid biopsy for neurodegeneration) and RNA Clarity (RNA therapeutic QC), and offers end-to-end methylation, whole-genome, RNA, cfDNA, and telomere sequencing services from its CAP/CLIA-certified Renew Labs facility.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 97.6% AUC for Alzheimer's disease discrimination in multi-disease cohorts
+7 more records
Product overview1 text field

Renew Biotechnologies offers an integrated platform of clinical diagnostic products and sequencing services powered by proprietary native-read and long-read sequencing technologies. The core product portfolio includes three main offerings: NeuroLens® (blood-based liquid biopsy for neurodegeneration detection), RNA Clarity™ (RNA vaccine QC), and MethylMap™ (native-read methylation sequencing). These clinical products are complemented by a comprehensive suite of sequencing services spanning genomic, epigenomic, and transcriptomic analysis, including Direct Whole Methylome Sequencing, Direct RNA Sequencing, cDNA Sequencing, Whole Genome Sequencing, and Telomere Sequencing. The integrated technology model combines proprietary sequencing workflows with CAP/CLIA laboratory infrastructure to transform molecular signals into clinical and research applications.

Product and service10 records
1NeuroLens®
CategoryClinical Diagnostics
Description

Blood-based liquid biopsy test for detecting neuron- and glia-associated cfDNA signals linked to active neurodegeneration, enabling early detection and monitoring of Alzheimer's, Parkinson's, and ALS. For biopharma, healthcare providers, and clinical laboratories.

2RNA Clarity™
CategoryQuality Control Product
Description

Native RNA sequencing workflow for multi-attribute RNA therapeutic characterization, quality control, and lot release testing, preserving RNA modifications without reverse transcription artifacts. For RNA therapeutic developers and manufacturers.

3MethylMap™
CategorySequencing Product
Description

Native-read methylation sequencing product enabling broader epigenetic coverage and higher-fidelity methylation profiling compared to traditional bisulfite or array methods, for translational methylation programs.

4Direct Whole Methylome Sequencing (gDNA)
CategorySequencing Service
Description

End-to-end sequencing service for genome-wide methylation analysis using native-read technology that captures sequence, methylation, and hydroxymethylation signals simultaneously, covering up to 98% of the 28.1 million CpG methylation sites.

5Direct Methylation Sequencing (cfDNA)
CategorySequencing Service
Description

Specialized sequencing service for analyzing cell-free DNA methylation patterns, enabling liquid biopsy applications and non-invasive biomarker detection.

6Direct Targeted Methylation Sequencing (gDNA)
CategorySequencing Service
Description

Hybrid capture-based long-read sequencing service combining Agilent SureSelect enrichment with native Oxford Nanopore sequencing for integrated analysis of genetic variation and DNA methylation in defined genomic regions.

7Whole Genome Sequencing
CategorySequencing Service
Description

Comprehensive genomic sequencing service covering the entire genome for variant detection, structural analysis, and comprehensive genomic profiling.

8Direct RNA Sequencing
CategorySequencing Service
Description

Native RNA sequencing that captures full-length polyadenylated RNA transcripts without reverse transcription or cDNA synthesis, preserving epigenetic modifications and providing accurate long-read sequencing.

9cDNA Sequencing
CategorySequencing Service
Description

Long-read cDNA sequencing service for transcriptomic analysis, capturing full-length isoforms and complex splicing patterns for biomarker discovery and cancer research.

10Telomere Sequencing
CategorySequencing Service
Description

Specialized sequencing service for telomere length estimation and analysis, supporting research at the intersection of aging, cancer, and neurodegeneration.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-24
Description

Strategic collaboration to generate the largest clinical multi-omics dataset for neurological disorders including Alzheimer's, Parkinson's, and ALS. Renew provides clinical laboratory infrastructure and multi-omics data generation capabilities; Valinor provides proprietary machine learning architectures for predictive model development. Companies jointly own resulting datasets with Valinor as exclusive AI partner authorized to train foundation models for biopharmaceutical customers.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

Renew serves as the clinical testing provider for Path Fertility's NOA Guide, an epigenetic diagnostic test for male infertility. The test leverages Renew's native-read sequencing technology to detect sperm-derived cell-free DNA in seminal samples for surgical decision-making in men with non-obstructive azoospermia.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-20
Description

Collaboration to develop and launch Direct Whole Methylome Sequencing (dWMS) product. The partnership combines Oxford Nanopore's rapid, accessible sequencing technology with Renew's proprietary methylation assays to overcome limitations of traditional bisulfite sequencing and methylation microarrays. Aims to redefine standards in epigenetic research and clinical applications.

Strategic tierSupportingTypeTechnology or Integration
Description

Direct Targeted Methylation Sequencing (dTMS) products and services combine Agilent SureSelect enrichment with Renew's native-read workflow for targeted genetic and epigenetic analysis in defined genomic regions.

Strategic tierSupportingTypeTechnology or Integration
Description

Custom hybridization panels developed with Twist support Oxford Nanopore-based long-read targeted sequencing for complex genomic regions and application-specific targets.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Strategic distribution relationship supports NeuroLens products and direct methylation sequencing services for blood-based brain cell death testing, extending Renew's market reach for its neurodegenerative disease diagnostic products.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Research collaboration with BYU researchers for validation studies of blood tests for early Alzheimer's disease detection. BYU Life Sciences team leads validation study in collaboration with University of Kansas Alzheimer's Disease Research Center.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaborative validation study for early Alzheimer's disease detection blood test, working with BYU researchers to conduct clinical validation and advance toward earlier detection, disease progression monitoring, and foundation for new diagnostic tools.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Core technology platform partner and direct player in long-read sequencing. Both companies commercialize Oxford Nanopore-based workflows for methylation and native-read applications targeting biopharma and research customers, making them the closest direct comparable.

TypeDirect peer
Description

Long-read sequencing platform competitor with HiFi technology used for methylation detection, structural variant analysis, and translational research. Overlaps directly with Renew's whole-genome, epigenomic, and complex-region sequencing services.

TypeDirect peer
Description

Sequencing platform competitor offering short-read and AVITI systems, with growing presence in epigenomic and translational applications. Comparable to Renew as a sequencing technology company targeting similar research and clinical research customers.

TypeDirect peer
Description

Leader in cell-free DNA-based diagnostics, including oncology and reproductive health. Overlaps with Renew's cfDNA methylation work (NeuroLens) and Path Fertility NOA Guide partnership, and both operate CLIA-certified clinical labs.

TypeDirect peer
Description

Liquid biopsy and cfDNA analytics company focused on oncology. Comparable to Renew in applying methylation and cfDNA analytics to clinical diagnostics, and operates a similar CAP/CLIA laboratory model serving biopharma and providers.

TypeBroad incumbent
Description

Established molecular diagnostics and sample-preparation company with broad methylation, liquid biopsy, and NGS-adjacent product portfolios. Comparable to Renew as a sample-to-insight provider, but operates at a much larger scale and across many more indications.

TypeBroad incumbent
Description

Major molecular diagnostics company (Cologuard, Oncotype DX) with growing presence in methylation-based liquid biopsy. Comparable to Renew in commercializing methylation biomarkers for clinical use, but at a far more mature commercial stage.

TypeEmerging player
Description

Single-cell and spatial genomics platform with adjacency to long-read and multi-omic workflows. Comparable to Renew as a developer of differentiated genomics tools targeting translational and clinical research customers.

TypeEmerging player
Description

cfDNA methylation-based diagnostics company focused on early cancer detection. Directly comparable to Renew in applying methylation signatures to liquid biopsy for non-invasive disease detection.

TypeBroad incumbent
Description

Clinical molecular diagnostics laboratory offering oncology-focused sequencing and methylation services. Comparable to Renew as a CAP/CLIA-certified lab serving biopharma and clinical customers with genomic and epigenomic testing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Renew Biotechnologies

Genomic Sequencing & Diagnosticsrenewbt.com

Renew Biotechnologies develops native-read and long-read sequencing-based diagnostic products and services, including NeuroLens (neurodegeneration liquid biopsy), RNA Clarity, and MethylMap, serving biopharma, academic researchers, and clinical laboratories through a CAP/CLIA-certified lab.

What Renew Biotechnologies does

Renew Biotechnologies, founded in 2022 and headquartered in Provo, Utah, develops diagnostic and translational research solutions built on its proprietary NESSI-Seq native-read sequencing platform, which leverages Oxford Nanopore long-read technology to simultaneously detect DNA sequence, methylation, and hydroxymethylation patterns without bisulfite conversion or PCR amplification biases. The portfolio includes three commercial products — NeuroLens (a blood-based liquid biopsy for detecting neuron- and glia-derived cfDNA signals linked to active neurodegeneration in Alzheimer's, Parkinson's, and ALS), RNA Clarity (a native RNA sequencing workflow for RNA therapeutic characterization, QC, and lot release), and MethylMap (native-read methylation sequencing for translational methylation programs) — alongside a service catalogue spanning whole-genome, whole methylome, cfDNA methylation, targeted methylation, direct RNA, cDNA, and telomere sequencing, delivered through a 20,000-square-foot CAP/CLIA-certified Renew Labs facility with a custom in-house LIMS. The company also operates a wholly-owned subsidiary, Resonant, focused on neurodegenerative disease blood testing, and serves as the clinical testing provider for Path Fertility's NOA Guide epigenetic diagnostic for non-obstructive azoospermia.

The business operates a hybrid revenue model: professional-services revenue from CAP/CLIA clinical testing and end-to-end sequencing projects, supplemented by product/kits and reagents sales (NeuroLens, RNA Clarity, MethylMap). Pricing is fully quote-based and project-specific with no published tiers, and the company sells through a hybrid direct enterprise sales motion and channel partners, most notably Boston Heart Diagnostics for NeuroLens distribution and Valinor Discovery as an exclusive AI co-development partner authorized to train predictive models on jointly-owned neurological multi-omics datasets. Customers are segmented horizontally across biopharma and drug development companies, academic and clinical research institutions, healthcare providers and clinical laboratories, and fertility clinics, with sales cycles supported by content marketing, scientific publications, conference presentations, and website-driven partnership inquiries.

Strategically, the company is executing an offensive expansion rather than a defensive pivot: it has added new product lines (proteomics "available soon"), a new clinical vertical (reproductive health via Path Fertility), a new brand (Resonant) targeting neurodegeneration, a core technology partnership with Oxford Nanopore, supporting technology integrations with Agilent and Twist Bioscience, academic validation collaborations with BYU and the University of Kansas Alzheimer's Disease Research Center, and an exclusive data/AI partnership with Valinor Discovery — collectively pointing to a coordinated push to translate proprietary native-read sequencing into both clinical diagnostics and data-anchored biopharma services.

Renew Biotechnologies firmographics

Firmographics
Name
Renew Biotechnologies
Legal name
Renew Biotechnologies
Website
https://renewbt.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Renew Biotechnologies develops native-read and long-read sequencing-based diagnostic products and services, including NeuroLens (neurodegeneration liquid biopsy), RNA Clarity, and MethylMap, serving biopharma, academic researchers, and clinical laboratories through a CAP/CLIA-certified lab.
Ownership category
akta.pro rank

Renew Biotechnologies industry classification

Industry
Product category
Genomic Sequencing & Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Genomic sequencing services
  • Epigenetic diagnostics
  • Liquid biopsy testing
  • Native-read methylation
  • Clinical laboratory services

Where Renew Biotechnologies is headquartered

Location

Headquarters

HQ city
Provo
HQ country
United States
HQ region
North America

Markets served

Renew Biotechnologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Clinical Testing Services: CAP/CLIA certified laboratory services providing clinical-grade genomic and epigenetic analysis for diagnostic and monitoring applications, including NeuroLens neuron cell-death testing and Path Fertility NOA Guide diagnostic services.
  2. Sequencing Services: End-to-end sequencing services supporting genomic, epigenomic, and transcriptomic analysis from experimental design through bioinformatics and data delivery. Includes direct whole methylome sequencing, whole genome sequencing, direct RNA sequencing, and cDNA sequencing.
  3. Products: Sale of proprietary kits and reagents including NeuroLens (neuron cell-death test), RNA Clarity (RNA vaccine QC), and MethylMap (methylation sequencing) products for customer use in their own laboratories.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Renew Biotechnologies product offering

Product offering

Core offering

Renew Biotechnologies develops and delivers clinical diagnostic products and sequencing services built on its proprietary native-read and long-read sequencing platform (NESSI-Seq / Direct Whole Methylome Sequencing). The company sells diagnostic products such as NeuroLens (blood-based liquid biopsy for neurodegeneration) and RNA Clarity (RNA therapeutic QC), and offers end-to-end methylation, whole-genome, RNA, cfDNA, and telomere sequencing services from its CAP/CLIA-certified Renew Labs facility.

Product overview

Renew Biotechnologies offers an integrated platform of clinical diagnostic products and sequencing services powered by proprietary native-read and long-read sequencing technologies. The core product portfolio includes three main offerings: NeuroLens® (blood-based liquid biopsy for neurodegeneration detection), RNA Clarity™ (RNA vaccine QC), and MethylMap™ (native-read methylation sequencing). These clinical products are complemented by a comprehensive suite of sequencing services spanning genomic, epigenomic, and transcriptomic analysis, including Direct Whole Methylome Sequencing, Direct RNA Sequencing, cDNA Sequencing, Whole Genome Sequencing, and Telomere Sequencing. The integrated technology model combines proprietary sequencing workflows with CAP/CLIA laboratory infrastructure to transform molecular signals into clinical and research applications.

Differentiator

Problem solved

Functional benefit

Brands

  • NeuroLens®: Blood-based liquid biopsy test for detecting neuron- and glia-associated cfDNA signals linked to active neurodegeneration
  • RNA Clarity™
  • MethylMap™
  • Resonant
  • Renew Labs

Products and services

  • NeuroLens® Blood-based liquid biopsy test for detecting neuron- and glia-associated cfDNA signals linked to active neurodegeneration, enabling early detection and monitoring of Alzheimer's, Parkinson's, and ALS. For biopharma, healthcare providers, and clinical laboratories.
  • RNA Clarity™ Native RNA sequencing workflow for multi-attribute RNA therapeutic characterization, quality control, and lot release testing, preserving RNA modifications without reverse transcription artifacts. For RNA therapeutic developers and manufacturers.
  • MethylMap™ Native-read methylation sequencing product enabling broader epigenetic coverage and higher-fidelity methylation profiling compared to traditional bisulfite or array methods, for translational methylation programs.
  • Direct Whole Methylome Sequencing (gDNA) End-to-end sequencing service for genome-wide methylation analysis using native-read technology that captures sequence, methylation, and hydroxymethylation signals simultaneously, covering up to 98% of the 28.1 million CpG methylation sites.
  • Direct Methylation Sequencing (cfDNA) Specialized sequencing service for analyzing cell-free DNA methylation patterns, enabling liquid biopsy applications and non-invasive biomarker detection.
  • Direct Targeted Methylation Sequencing (gDNA) Hybrid capture-based long-read sequencing service combining Agilent SureSelect enrichment with native Oxford Nanopore sequencing for integrated analysis of genetic variation and DNA methylation in defined genomic regions.
  • Whole Genome Sequencing Comprehensive genomic sequencing service covering the entire genome for variant detection, structural analysis, and comprehensive genomic profiling.
  • Direct RNA Sequencing Native RNA sequencing that captures full-length polyadenylated RNA transcripts without reverse transcription or cDNA synthesis, preserving epigenetic modifications and providing accurate long-read sequencing.
  • cDNA Sequencing Long-read cDNA sequencing service for transcriptomic analysis, capturing full-length isoforms and complex splicing patterns for biomarker discovery and cancer research.
  • Telomere Sequencing Specialized sequencing service for telomere length estimation and analysis, supporting research at the intersection of aging, cancer, and neurodegeneration.

Quantifiable outcome

  • 97.6% AUC for Alzheimer's disease discrimination in multi-disease cohorts
  • +7 more outcomes

Companies that use Renew Biotechnologies

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Renew Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature7 records

Renew Biotechnologies partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and supporting.

  • Valinor DiscoverycoreStrategic or Co-development Partner · 24 February 2026Strategic collaboration to generate the largest clinical multi-omics dataset for neurological disorders including Alzheimer's, Parkinson's, and ALS. Renew provides clinical laboratory infrastructure and multi-omics data generation capabilities; Valinor provides proprietary machine learning architectures for predictive model development. Companies jointly own resulting datasets with Valinor as exclusive AI partner authorized to train foundation models for biopharmaceutical customers.
  • Path FertilitysupportingStrategic or Co-development Partner · 29 January 2026Renew serves as the clinical testing provider for Path Fertility's NOA Guide, an epigenetic diagnostic test for male infertility. The test leverages Renew's native-read sequencing technology to detect sperm-derived cell-free DNA in seminal samples for surgical decision-making in men with non-obstructive azoospermia.
  • Oxford Nanopore TechnologiescoreTechnology or Integration · 20 January 2025Collaboration to develop and launch Direct Whole Methylome Sequencing (dWMS) product. The partnership combines Oxford Nanopore's rapid, accessible sequencing technology with Renew's proprietary methylation assays to overcome limitations of traditional bisulfite sequencing and methylation microarrays. Aims to redefine standards in epigenetic research and clinical applications.
  • Agilent TechnologiessupportingTechnology or IntegrationDirect Targeted Methylation Sequencing (dTMS) products and services combine Agilent SureSelect enrichment with Renew's native-read workflow for targeted genetic and epigenetic analysis in defined genomic regions.
  • Twist BiosciencesupportingTechnology or IntegrationCustom hybridization panels developed with Twist support Oxford Nanopore-based long-read targeted sequencing for complex genomic regions and application-specific targets.
  • Boston Heart DiagnosticssupportingChannel Partner/ Reseller/ DistributorStrategic distribution relationship supports NeuroLens products and direct methylation sequencing services for blood-based brain cell death testing, extending Renew's market reach for its neurodegenerative disease diagnostic products.
  • Brigham Young UniversitysupportingStrategic or Co-development PartnerResearch collaboration with BYU researchers for validation studies of blood tests for early Alzheimer's disease detection. BYU Life Sciences team leads validation study in collaboration with University of Kansas Alzheimer's Disease Research Center.
  • University of Kansas Alzheimer's Disease Research CentersupportingStrategic or Co-development PartnerCollaborative validation study for early Alzheimer's disease detection blood test, working with BYU researchers to conduct clinical validation and advance toward earlier detection, disease progression monitoring, and foundation for new diagnostic tools.

Scale indicators1 record

Recent moves5 records

Expansion highlights6 records

Renew Biotechnologies competitors and assessment

Company assessment

Direct peers

  • Oxford Nanopore Technologies: Core technology platform partner and direct player in long-read sequencing. Both companies commercialize Oxford Nanopore-based workflows for methylation and native-read applications targeting biopharma and research customers, making them the closest direct comparable.
  • Pacific Biosciences: Long-read sequencing platform competitor with HiFi technology used for methylation detection, structural variant analysis, and translational research. Overlaps directly with Renew's whole-genome, epigenomic, and complex-region sequencing services.
  • Element Biosciences: Sequencing platform competitor offering short-read and AVITI systems, with growing presence in epigenomic and translational applications. Comparable to Renew as a sequencing technology company targeting similar research and clinical research customers.
  • Natera: Leader in cell-free DNA-based diagnostics, including oncology and reproductive health. Overlaps with Renew's cfDNA methylation work (NeuroLens) and Path Fertility NOA Guide partnership, and both operate CLIA-certified clinical labs.
  • Guardant Health: Liquid biopsy and cfDNA analytics company focused on oncology. Comparable to Renew in applying methylation and cfDNA analytics to clinical diagnostics, and operates a similar CAP/CLIA laboratory model serving biopharma and providers.

Broad incumbents

  • QIAGEN: Established molecular diagnostics and sample-preparation company with broad methylation, liquid biopsy, and NGS-adjacent product portfolios. Comparable to Renew as a sample-to-insight provider, but operates at a much larger scale and across many more indications.
  • Exact Sciences: Major molecular diagnostics company (Cologuard, Oncotype DX) with growing presence in methylation-based liquid biopsy. Comparable to Renew in commercializing methylation biomarkers for clinical use, but at a far more mature commercial stage.
  • NeoGenomics: Clinical molecular diagnostics laboratory offering oncology-focused sequencing and methylation services. Comparable to Renew as a CAP/CLIA-certified lab serving biopharma and clinical customers with genomic and epigenomic testing.

Emerging players

  • 10x Genomics: Single-cell and spatial genomics platform with adjacency to long-read and multi-omic workflows. Comparable to Renew as a developer of differentiated genomics tools targeting translational and clinical research customers.
  • Singlera Genomics: cfDNA methylation-based diagnostics company focused on early cancer detection. Directly comparable to Renew in applying methylation signatures to liquid biopsy for non-invasive disease detection.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Renew Biotechnologies social profiles

Digital presence

Renew Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Renew Biotechnologies leadership team

Management profile

Number of profiles

Profiles13 records

Renew Biotechnologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Renew Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Renew Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Renew Biotechnologies

What does Renew Biotechnologies do?

Renew Biotechnologies develops and delivers clinical diagnostic products and sequencing services built on its proprietary native-read and long-read sequencing platform (NESSI-Seq / Direct Whole Methylome Sequencing). The company sells diagnostic products such as NeuroLens (blood-based liquid biopsy for neurodegeneration) and RNA Clarity (RNA therapeutic QC), and offers end-to-end methylation, whole-genome, RNA, cfDNA, and telomere sequencing services from its CAP/CLIA-certified Renew Labs facility.

Is Renew Biotechnologies a public or private company?

Renew Biotechnologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Renew Biotechnologies founded?

Renew Biotechnologies was founded in 2022. It employs 11 to 50 people.

Where is Renew Biotechnologies based?

Renew Biotechnologies is headquartered in Provo, United States, in the North America region.

How does Renew Biotechnologies make money?

Three revenue lines are on record. Clinical Testing Services are the primary driver. The others are sequencing Services and products.

Who are Renew Biotechnologies's main competitors?

Direct peers on record are Oxford Nanopore Technologies, Pacific Biosciences, Element Biosciences, Natera and Guardant Health. Broad incumbents are QIAGEN, Exact Sciences and NeoGenomics. Emerging players are 10x Genomics and Singlera Genomics.

Does Renew Biotechnologies have an API?

No public API is recorded for Renew Biotechnologies.

What industry is Renew Biotechnologies in?

Renew Biotechnologies's product category is Genomic Sequencing & Diagnostics. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAGANAF, Epigenomics & Chromatin Profiling Services. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRenew Biotechnologies Named 2026 "Biomarker Discovery Platform of the Year" by BioTech BreakthroughRenew Biotechnologies was named Biomarker Discovery Platform of the Year by BioTech Breakthrough for its NeuroLens platform, which analyzes cell-free DNA methylation in blood to identify signals from specific neural cell types. The platform's research identified cell-type-associated signatures in Alzheimer's, Parkinson's, and ALS, but the findings remain proof-of-concept requiring further validation.PR NewswireRenew Biotechnologies Enters Collaboration to Evaluate NeuroLens® in Multiple Sclerosis and Related Neuroimmunologic DiseasesRenew Biotechnologies announced a clinical development collaboration with Mayo Clinic to evaluate its NeuroLens cell-free DNA approach in multiple sclerosis and related neuroimmunologic diseases. The study will examine cell-of-origin signatures associated with cell death, aiming to provide minimally invasive biomarkers for CNS injury. The research initially focuses on MS, with potential expansion to other diseases.PR NewswireRenew Biotechnologies Publishes Peer-Reviewed Research Advancing Cell-Type-Associated Biomarkers of NeurodegenerationRenew Biotechnologies announced the publication of research demonstrating that native DNA methylation analysis can identify neuron-associated cfDNA signatures in blood for neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS. The study shows that this blood-based biomarker approach can provide cellular origin insights and improve disease detection accuracy. The company plans to continue validation studies and develop the NeuroLens® platform into a clinical diagnostic tool.MorningstarRenew Biotechnologies Publishes Peer-Reviewed Research Advancing Cell-Type-Associated Biomarkers of NeurodegenerationRenew Biotechnologies published peer-reviewed research in Frontiers in Neurology showing native DNA methylation analysis identifies neuron-associated cell-free DNA signatures in blood for Alzheimer's, Parkinson's, and ALS. The study analyzed 137 blood samples and achieved disease discrimination with AUC values exceeding 0.85. The findings support the development of NeuroLens, a blood-based cfDNA methylation platform.AijournRenew Biotechnologies Unifies Wasatch BioLabs and Resonant Under One Brand to Advance Sequencing-Based DiagnosticsRenew Biotechnologies announced the consolidation of its two subsidiaries, Wasatch BioLabs and Resonant, under the unified Renew Biotechnologies brand to create a single platform for sequencing-based diagnostics and clinical testing. The consolidation is purely a brand rationalization exercise—no ownership, management, or operational changes occur, with existing services, contracts, and client relationships continuing uninterrupted. The unified company aims to accelerate translation of advanced molecular technologies into clinical applications, building on capabilities across long-read sequencing, assay development, and products like NeuroLens for Alzheimer's disease detection.PR NewswireRenew Biotechnologies Unifies Wasatch BioLabs and Resonant Under One Brand to Advance Sequencing-Based DiagnosticsRenew Biotechnologies announced the consolidation of its subsidiaries Wasatch BioLabs and Resonant under the single Renew Biotechnologies brand, creating a unified platform for sequencing-based diagnostics, translational research, and clinical testing. The company clarified this is a brand consolidation only, not an acquisition, merger, or ownership change, with all existing services, contracts, and operations continuing uninterrupted under the unified brand. Wasatch BioLabs brings expertise in long-read and native-read sequencing, while Resonant contributes its NeuroLens blood-based liquid biopsy diagnostic technology for neurological conditions like Alzheimer's disease.RenewbtNGS Liquid Biopsy Technologies: Transforming Clinical DiagnosticsThis article provides an overview of next-generation sequencing (NGS) technologies in liquid biopsy for clinical diagnostics, highlighting how advances in molecular profiling are enabling minimally invasive analysis of circulating tumor DNA for cancer detection, treatment monitoring, and precision medicine applications. The global NGS market was valued at USD 9.19 billion in 2023 and is projected to reach USD 66.04 billion by 2033, growing at a compound annual growth rate of 21.8%. Renew Biotechnologies is positioned as a leader in developing proprietary nanopore technologies to address ongoing challenges in cfDNA-based liquid biopsies, including sensitivity, data interpretation, and standardization issues.Scientist LiveValinor and Renew partner to generate clinical multi-omics dataset for neurological disease model developmentValinor Discovery and Renew Biotechnologies have partnered to generate a comprehensive clinical multi-omics dataset focused on neurological disorders, including Parkinson's disease, ALS, and Alzheimer’s, to improve disease prediction and therapeutic responses. The collaboration leverages Renew's clinical and sequencing infrastructure with Valinor's machine learning models to identify disease patterns. The initiative aims to enhance decision-making and reduce costs in neurology drug development, with datasets jointly owned by both parties.BioSpaceValinor and Renew Launch Partnership to Generate Largest Clinical Multi-Omics Dataset for Neurological Disease Model DevelopmentValinor Discovery and Renew Biotechnologies announced a strategic collaboration to generate the largest clinical multi-omics dataset to date for neurological disorders, including Alzheimer's disease, Parkinson's disease, and ALS. The partnership combines Renew's clinical laboratory infrastructure and multi-omics data generation capabilities with Valinor's proprietary machine learning architectures to develop predictive models for disease onset and therapeutic responses. The companies will jointly own the resulting datasets, with Valinor serving as the exclusive AI partner authorized to train models, aiming to accelerate biopharma R&D and reduce development costs in neurology.